


Appendix 2. Step-by-step therapy for patients with arterial hypertension and chronic kidney disease (ESH, 2023*)



CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; CCBs, calcium channel blockers; T/TL, thiazide, thiazide-like; MRAs, mineralocorticoid receptor antagonists; BAB, beta adrenoblockers; SGLT2, sodium-glucose cotransporter inhibitors 2.

*Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. *J Hypertens.* 2023;41(12):1874–2071. doi: [10.1097/HJH.0000000000003480](https://doi.org/10.1097/HJH.0000000000003480)